NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

TPST

Tempest Therapeutics Inc

Apr 21 • 01:34PM ET

7.20

Dollar change -0.08
Percentage change -1.10	%

Healthcare • Biotechnology • USA • NASD

Peers: IMMP ADAP ATNM AGEN AFMD HOOK KALA COGT ONCY MRKR

| Held by: VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-19.54	Insider Own	9.21%	Shs Outstand	3.38M	Perf Week	15.76%
Market Cap	25.35M	Forward P/E	-	EPS next Y	-18.34	Insider Trans	0.00%	Shs Float	3.20M	Perf Month	-31.63%
Income	-41.84M	PEG	-	EPS next Q	-3.54	Inst Own	6.21%	Short Float	3.93%	Perf Quarter	-40.17%
Sales	0.00M	P/S	-	EPS this Y	23.63%	Inst Trans	-	Short Ratio	2.02	Perf Half Y	-50.10%
Book/sh	5.65	P/B	1.27	EPS next Y	-23.18%	ROA	-87.51%	Short Interest	0.13M	Perf Year	-83.06%
Cash/sh	8.60	P/C	0.84	EPS next 5Y	2.13%	ROE	-182.35%	52W Range	5.35 - 49.27	Perf YTD	-33.63%
Dividend Est.	-	P/FCF	-	EPS past 5Y	50.16%	ROI	-153.45%	52W High	-85.39%	Beta	-1.56
Dividend TTM	-	Quick Ratio	2.21	Sales past 5Y	0.00%	Gross Margin	-	52W Low	34.59%	ATR (14)	0.85
Dividend Ex-Date	-	Current Ratio	2.21	EPS Y/Y TTM	-220.54%	Oper. Margin	-	RSI (14)	38.38	Volatility	10.64% 11.57%
Employees	25	Debt/Eq	0.80	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	94.00
Option/Short	No / Yes	LT Debt/Eq	0.43	EPS Q/Q	9.72%	Payout	-	Rel Volume	0.75	Prev Close	7.28
Sales Surprise	-	EPS Surprise	-23.08%	Sales Q/Q	-	Earnings	Mar 27 AMC	Avg Volume	62.12K	Price	7.20
SMA20	-13.95%	SMA50	-27.68%	SMA200	-49.77%	Trades		Volume	29,824	Change	-1.10%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform
Apr-10-25	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-14-24	Initiated	Scotiabank	Sector Outperform	$13
Feb-08-24	Initiated	Jefferies	Buy	$15

Today 08:00AM	Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP (GlobeNewswire)
Apr-10-25 11:05AM	TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up (Zacks) -18.04%
Apr-09-25 04:30PM	Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value (GlobeNewswire) +9.87%
Mar-27-25 04:10PM	Tempest Reports Year End 2024 Financial Results and Provides Business Update (GlobeNewswire) -8.08%
Mar-25-25 04:30PM	Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Mar-13-25 08:00AM	FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP) (GlobeNewswire)
Feb-10-25 08:00AM	Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (GlobeNewswire)
Feb-07-25 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-06-25 08:00AM	Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) (GlobeNewswire)
Dec-06-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-05-24 09:00PM	A Reverse Aging Gurus Trail of Failed Businesses (The Wall Street Journal)
Nov-25-24 04:30PM	Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 04:21PM	Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -10.50%
08:00AM	Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma (GlobeNewswire)
Oct-10-24 07:01AM	Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial (GlobeNewswire) -18.52%
07:00AM	Loading…
07:00AM	Tempest Extends Limited Duration Stockholder Rights Plan (GlobeNewswire)
Sep-20-24 04:30PM	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-18-24 08:00AM	Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs (GlobeNewswire) -6.62%
Sep-05-24 08:00AM	Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) +5.04%
Aug-23-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-21-24 08:00AM	Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance (GlobeNewswire)
Aug-15-24 08:00AM	Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma (GlobeNewswire) +30.25%
Aug-08-24 04:56PM	Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -14.18%
Jun-20-24 08:13AM	Why Is Tempest Therapeutics (TPST) Stock Up 45% Today? (InvestorPlace) -29.47%
08:00AM	Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm (GlobeNewswire)
07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-18-24 06:22PM	Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Jun-07-24 04:30AM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-21-24 08:00AM	Tempest to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 04:29PM	Tempest Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -6.34%
04:05PM	Loading…
Apr-26-24 04:05PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-09-24 08:00AM	Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting (GlobeNewswire)
Apr-04-24 08:00AM	Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications (GlobeNewswire) -12.20%
Mar-19-24 09:53PM	TPST Stock Earnings: Tempest Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
04:25PM	Tempest Reports Year End 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 08:00AM	Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types (GlobeNewswire)
Mar-05-24 04:30PM	Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting (GlobeNewswire) +16.09%
Feb-26-24 08:00AM	Tempest to Present at the 44th Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-02-24 04:30PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-05-24 04:05PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.60%
Dec-01-23 04:15PM	Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-23 08:00AM	Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +9.25%
Nov-08-23 05:17PM	Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -8.74% +16.31%
Oct-12-23 08:25AM	Why Is Tempest Therapeutics (TPST) Stock Down 35% Today? (InvestorPlace) -59.26%
Oct-11-23 04:29PM	TPST Stock: 7 Things to Know About Tempest Therapeutics (InvestorPlace) +3,972.53%
08:01AM	Tempest Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
08:00AM	Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study (GlobeNewswire)
07:41AM	Why Is Tempest Therapeutics (TPST) Stock Up 325% Today? (InvestorPlace)
Oct-10-23 04:05PM	Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Sep-19-23 08:00AM	Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development (GlobeNewswire)
Sep-05-23 08:00AM	Tempest to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 04:13PM	Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +5.50%
Jul-19-23 08:00AM	Tempest Announces Publication in Cancer Research Communications Highlighting TPST-1495 Significantly Increased Potency Against Prostaglandin-Driven Tumor Models by Blocking EP2 and EP4 Together (GlobeNewswire)
May-31-23 04:05PM	Tempest to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) -5.85% -5.88%
May-25-23 05:00PM	Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers (GlobeNewswire) -9.76%
May-19-23 04:05PM	Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-10-23 04:15PM	Tempest Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 08:00AM	Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire) +23.26%
Apr-27-23 04:58PM	Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma (GlobeNewswire)
Apr-26-23 06:41PM	Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting (GlobeNewswire) -6.74%
Apr-17-23 09:00AM	Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting (GlobeNewswire) +25.42%
Mar-22-23 05:26PM	Tempest Reports Year End 2022 Financial Results and Provides Business Update (GlobeNewswire) +6.52%
Mar-15-23 04:05PM	Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting (GlobeNewswire)
Mar-14-23 04:30PM	Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting (GlobeNewswire) +15.79%
Nov-22-22 04:05PM	Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-10-22 09:00AM	Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer (GlobeNewswire)
Nov-08-22 08:00AM	Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) -12.09%
Nov-02-22 08:00AM	Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting (GlobeNewswire) +8.72%
Oct-06-22 08:00AM	Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit (GlobeNewswire)
Sep-07-22 08:00AM	Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +11.40%
Aug-15-22 08:00AM	Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire) +15.81%
Jul-07-22 08:00AM	Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference (GlobeNewswire) +11.93%
Jun-09-22 08:00AM	Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance (GlobeNewswire)
Jun-06-22 04:05PM	Tempest to Present at the Jefferies Healthcare Conference (GlobeNewswire) -12.50%
May-26-22 04:57PM	Tempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual Meeting (GlobeNewswire) -26.68%
May-13-22 08:00AM	Tempest Reports First Quarter 2022 Financial Results and Provides Corporate Highlights (GlobeNewswire) +5.88%
Apr-27-22 10:01AM	Tempest Announces Oral and Poster Presentations at the Upcoming 2022 ASCO Annual Meeting (GlobeNewswire) +30.08%
08:00AM	Tempest Announces Private Placement Financing of $15 Million (GlobeNewswire)
Apr-08-22 01:00PM	Tempest Presents Promising Preclinical Data on Two Oncology Programs at the 2022 AACR Annual Meeting (GlobeNewswire)
Mar-29-22 04:00PM	Tempest Reports Year End 2021 Financial Results and Provides Business Update (GlobeNewswire) -7.89%
Mar-10-22 08:00AM	Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference (GlobeNewswire) -9.23%
Mar-08-22 04:30PM	Tempest to Present Two Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-09-22 08:00AM	Tempest to Present at the 11th Annual SVB Leerink Healthcare Conference (GlobeNewswire)
Nov-18-21 08:00AM	Tempest Announces First Patient Dosed with TPST-1495 in Combination with Pembrolizumab (GlobeNewswire)
Nov-12-21 07:00AM	Tempest Presents Data Supporting the Dual Mechanism of TPST-1495 as an Optimal Approach for Targeting the Prostaglandin Pathway in Cancer (GlobeNewswire)
Nov-10-21 04:05PM	Tempest Reports Third Quarter 2021 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Nov-09-21 08:00AM	Tempest to Present at Two Upcoming Investor Conferences in November (GlobeNewswire)
Nov-08-21 08:00AM	Tempest Further Bolsters Patent Portfolio with Issuance of Multiple Patents for TPST-1495 (GlobeNewswire)
Oct-01-21 08:00AM	Tempest Announces Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting (GlobeNewswire)
Sep-20-21 08:00AM	Tempest Announces First Patient Dosed in Randomized Study Evaluating TPST-1120 in First-Line Regimen for Hepatocellular Carcinoma in Clinical Collaboration with Roche (GlobeNewswire)
Sep-13-21 08:00AM	Tempest Enters into Exclusive License Agreement with the University of California for Novel Cancer Target (GlobeNewswire)
Sep-09-21 04:01PM	Tempest to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-12-21 04:01PM	Tempest Reports Second Quarter 2021 Financial Results and Provides Corporate Highlights (GlobeNewswire)
Aug-09-21 08:00AM	Tempest Announces Appointment of Ronit Simantov, M.D. to its Board of Directors (GlobeNewswire) +8.09%
Jul-09-21 08:00AM	Tempest to Participate in William Blair 2021 Biotech Focus Conference (GlobeNewswire) +49.38%
Jul-01-21 04:00PM	Tempest Announces Appointment of Christine Pellizzari to its Board of Directors (GlobeNewswire)

Tempest Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development and discovery of small molecule drugs for the treatment of cancer. The company was founded in 2011 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Versant Venture Capital VI, L.	Owner	Aug 12 '24	Proposed Sale	1.10	387,999	426,993		Aug 13 08:03 AM
Versant Venture Capital VI, L.	10% Owner	Aug 08 '24	Sale	1.35	400,000	540,040	597,940	Aug 12 08:33 PM
Versant Venture Capital VI, L.	10% Owner	Aug 12 '24	Sale	1.10	387,999	426,993	209,941	Aug 12 08:33 PM
Versant Venture Capital VI, L.	10% Owner	Aug 08 '24	Proposed Sale	18.03	400,000	7,210,532		Aug 09 03:41 PM
Brady Stephen R	President and CEO	Jul 03 '24	Buy	2.11	35,000	73,850	46,376	Jul 08 04:15 PM
Whiting Samuel	Chief Medical Officer	Jul 02 '24	Buy	2.13	4,672	9,951	9,573	Jul 03 07:35 PM
Trojanowski Justin	Corporate Controller	Jun 28 '24	Buy	2.16	7,500	16,200	22,168	Jul 02 04:15 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TPST

Tempest Therapeutics Inc

Upgrade your FINVIZ experience